C. Jimmy Lin, MD, PhD, MHS is the Chief Scientific Officer (CSO), Oncology at Natera and a TED Fellow. He comes from a long history as a pioneer in cancer genomics. Most recently, he led the clinical genomics program at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). Previously, at Johns Hopkins and Washington University in St. Louis, Lin was part of one of the first clinical genomics labs in academia and led the computational analyses of the first ever exome sequencing studies in cancer, including breast, colorectal, pancreatic, glioblastoma, medulloblastoma and melanoma.
Jimmy Lin, MD, PhD, MHS, ha dedicado su vida a la lucha contra el cáncer. Como jefe de ciencias y oncología en Natera (NASDAQ: NTRA), ha liderado el desarrollo en tecnologías para la detención de células cancerígenas en la sangre. Es fundador/presidente del Instituto de Genomas Inusuales, la primera plataforma en el mundo que permite a cualquier comunidad, el acceso a biotecnología para el entendimiento de diferentes enfermedades.
Geneticist and founder of the Rare Genomics Institute, an organization that allows patients to crowdsource funds and genomes to accelerate research of their rare genetic diseases.
Jimmy is the lead computational biologist for the ground-breaking cancer genome sequencing efforts from the Vogelstein Lab at Johns Hopkins. Their sequencing of the first 100+ cancer exomes in 5 different tissue types has helped lay the foundation for a revolution in cancer genomics. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at [ Ссылка ]
